EUVIMEDEUVIMED entdecken
Crossref

Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non‐remission acute myeloid leukaemia: A nationwide retrospective study

Kensuke Matsuda iD, Takaaki Konuma iD, Kyoko Fuse iD, Masayoshi Masuko, Koji Kawamura, Masahiro Hirayama, Naoyuki Uchida, Kazuhiro Ikegame, Atsushi Wake, Tetsuya Eto, Noriko Doki, Shigesaburo Miyakoshi und 12 weitere

British Journal of Haematology · 2023-04 · 201 (1) · 106-113

DOI: 10.1111/bjh.18530 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 25.10.2022. Verfasst von Kensuke Matsuda und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Cord Blood Stem Cell Transplantation, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic haematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for some patients with acute myeloid leukaemia (AML) who are refractory to chemotherapy. Cord blood transplantation (CBT) is a reasonable option in such cases because of its rapid availability. Recently, a growing number of human leucocyte antigen (HLA)‐haploidentical related donor HSCTs (haplo‐HSCTs) have been performed, although its effectiveness remains undetermined. Using the Japanese nationwide transplantation registry data, we identified 2438 patients aged ≥16 years who received CBT or haplo‐HSCT as their first transplant for non‐remission AML between January 2008 and December 2018. After 2:1 propensity score matching, 918 patients in the CBT group and 459 patients in the haplo‐HSCT group were selected. In this matched cohort, no significant difference in overall survival (OS) was observed between the CBT and haplo‐HSCT groups (hazard ratio [HR] of haplo‐HSCT to CBT 1.02, 95% confidence interval [CI] 0.89–1.16). Similarly, no significant difference in the cumulative incidence of relapse (HR 1.09, 95% CI 0.93–1.28) or non‐relapse mortality (HR 0.94, 95% CI 0.76–1.18). Subgroup analysis showed that CBT was significantly associated with preferable OS in patients receiving myeloablative conditioning. Our data showed comparable outcomes between haplo‐HSCT and CBT recipients with non‐remission AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cord Blood Stem Cell TransplantationGraft vs Host DiseaseHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteHumansRetrospective StudiesTransplantation, HaploidenticalNeoplasm Recurrence, LocalTransplantation Conditioning

Stichwörter der Autor:innen

acute myeloid leukaemiacord blood transplantationhaploidentical transplantationnon-remission

Autor:innen und Institutionen

  • Department of Haematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Haematology and Oncology, JR Tokyo General Hospital, Tokyo, Japan.
  • Department of Haematology and Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Department of Haematopoietic Cell Therapy, Niigata University Medical and Dental Hospital, Niigata, Japan.
  • Department of Haematology, Tottori University Hospital, Tottori, Japan.
  • Department of Paediatrics, Mie University Graduate School of Medicine, Tsu, Japan.

ORCID-Profile: Kensuke Matsuda, Takaaki Konuma, Kyoko Fuse, Hirohisa Nakamae, Yoshiko Atsuta, Junya Kanda

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Matsuda, K., Konuma, T., Fuse, K., Masuko, M., Kawamura, K., Hirayama, M., Uchida, N., Ikegame, K., Wake, A., Eto, T., Doki, N., Miyakoshi, S., Tanaka, M., Takahashi, S., Onizuka, M., Kato, K., Kimura, T., Ichinohe, T., Takayama, N., …, & Yanada, M. (2023). Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non‐remission acute myeloid leukaemia: A nationwide retrospective study. British Journal of Haematology, 201(1), 106-113. https://doi.org/10.1111/bjh.18530

Vancouver

Matsuda K, Konuma T, Fuse K, Masuko M, Kawamura K, Hirayama M, et al. Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non‐remission acute myeloid leukaemia: A nationwide retrospective study. British Journal of Haematology. 2023;201(1):106-113. doi:10.1111/bjh.18530

BibTeX
@article{Matsuda2023,
  author = {Matsuda, Kensuke and Konuma, Takaaki and Fuse, Kyoko and Masuko, Masayoshi and Kawamura, Koji and Hirayama, Masahiro and Uchida, Naoyuki and Ikegame, Kazuhiro and Wake, Atsushi and Eto, Tetsuya and Doki, Noriko and Miyakoshi, Shigesaburo and Tanaka, Masatsugu and Takahashi, Satoshi and Onizuka, Makoto and Kato, Koji and Kimura, Takafumi and Ichinohe, Tatsuo and Takayama, Nobuyuki and Kobayashi, Hikaru and Nakamae, Hirohisa and Atsuta, Yoshiko and Kanda, Junya and Yanada, Masamitsu},
  title = {Comparison of transplant outcomes between haploidentical transplantation and single cord blood transplantation in non‐remission acute myeloid leukaemia: A nationwide retrospective study},
  journal = {British Journal of Haematology},
  year = {2023},
  volume = {201},
  number = {1},
  pages = {106--113},
  doi = {10.1111/bjh.18530}
}
Kostenlos starten →